|
1
|
Azer SA: Overview of molecular pathways in
inflammatory bowel disease associated with colorectal cancer
development. Eur J Gastroenterol Hepatol. 25:271–281. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Raskov H, Pommergaard HC, Burcharth J and
Rosenberg J: Colorectal carcinogenesis - update and perspectives.
World J Gastroenterol. 20:18151–18164. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Newman NA, Votanopoulos KL, Stewart JH,
Shen P and Levine EA: Cytoreductive surgery and hyperthermic
intraperitoneal chemotherapy for colorectal cancer. Minerva Chir.
67:309–318. 2012.PubMed/NCBI
|
|
6
|
Hompes D, D'Hoore A, Van Cutsem E, Fieuws
S, Ceelen W, Peeters M, Van der Speeten K, Bertrand C, Legendre H
and Kerger J: The treatment of peritoneal carcinomatosis of
colorectal cancer with complete cytoreductive surgery and
hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with
oxaliplatin: A Belgian multicentre prospective phase II clinical
study. Ann Surg Oncol. 19:2186–2194. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fu Z, Shrubsole MJ, Smalley WE, Wu H, Chen
Z, Shyr Y, Ness RM and Zheng W: Association of meat intake and
meat-derived mutagen exposure with the risk of colorectal polyps by
histologic type. Cancer Prev Res (Phila). 4:1686–1697. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Piepoli A, Tavano F, Copetti M, Mazza T,
Palumbo O, Panza A, di Mola FF, Pazienza V, Mazzoccoli G, Biscaglia
G, et al: MiRNA expression profiles identify drivers in colorectal
and pancreatic cancers. PLoS One. 7:e336632012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Linnekamp JF, Wang X, Medema JP and
Vermeulen L: Colorectal cancer heterogeneity and targeted therapy,
A case for molecular disease subtypes. Cancer Res. 75:245–249.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Blander G and Guarente L: The Sir2 family
of protein deacetylases. Annu Rev Biochem. 73:417–435. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Casatta N, Porro A, Orlandi I, Brambilla L
and Vai M: Lack of Sir2 increases acetate consumption and decreases
extracellular pro-aging factors. Biochim Biophys Acta.
1833:593–601. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huffman DM, Grizzle WE, Bamman MM, Kim JS,
Eltoum IA, Elgavish A and Nagy TR: SIRT1 is significantly elevated
in mouse and human prostate cancer. Cancer Res. 67:6612–6618. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bradbury CA, Khanim FL, Hayden R, Bunce
CM, White DA, Drayson MT, Craddock C and Turner BM: Histone
deacetylases in acute myeloid leukaemia show a distinctive pattern
of expression that changes selectively in response to deacetylase
inhibitors. Leukemia. 19:1751–1759. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hida Y, Kubo Y, Murao K and Arase S:
Strong expression of a longevity-related protein, SIRT1, in Bowen's
disease. Arch Dermatol Res. 299:103–106. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stünkel W, Peh BK, Tan YC, Nayagam VM,
Wang X, Salto-Tellez M, Ni B, Entzeroth M and Wood J: Function of
the SIRT1 protein deacetylase in cancer. Biotechnol J. 2:1360–1368.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bass P, Carr N and Du Boulay C: Pathology:
A Core Text of Basic Pathological Processes with Self-Assessment
(2nd). Edinburgh: Churchill Livingstone. 2004.
|
|
17
|
Yang J, Guo R, Kang A, Chen X, Su B, Huang
X, Jin Y and Li Z: A novel histological typing and grading-scale
system of colorectal cancer. Nan Fang Yi Ke Da Xue Xue Bao.
34:169–173. 2014.(In Chinese). PubMed/NCBI
|
|
18
|
Dukes CE: The classification of cancer of
the rectum. J Pathol. 35:323–332. 1932. View Article : Google Scholar
|
|
19
|
Chueca E, Lanas A and Piazuelo E: Role of
gastrin-peptides in Barrett's and colorectal carcinogenesis. World
J Gastroenterol. 18:6560–6570. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fadri-Moskwik M, Weiderhold KN, Deeraksa
A, Chuang C, Pan J, Lin SH and Yu-Lee LY: Aurora B is regulated by
acetylation/deacetylation during mitosis in prostate cancer cells.
FASEB J. 26:4057–4067. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim SJ, Ao Z, Warnock G and McIntosh CH:
Incretin-stimulated interaction between β-cell Kv1.5 and Kvβ2
channel proteins involves acetylation/deacetylation by CBP/SirT1.
Biochem J. 451:227–234. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hishida T, Nozaki Y, Nakachi Y, Mizuno Y,
Iseki H, Katano M, Kamon M, Hirasaki M, Nishimoto M, Okazaki Y and
Okuda A: Sirt1, p53, and p38(MAPK) are crucial regulators of
detrimental phenotypes of embryonic stem cells with Max expression
ablation. Stem Cells. 30:1634–1644. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Muller PA and Vousden KH: p53 mutations in
cancer. Nat Cell Biol. 15:2–8. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Castro RE, Ferreira DM, Afonso MB,
Borralho PM, Machado MV, Cortez-Pinto H and Rodrigues CM:
miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat
liver and activated by disease severity in human non-alcoholic
fatty liver disease. J Hepatol. 58:119–25. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zannini L, Buscemi G, Kim JE, Fontanella E
and Delia D: DBC1 phosphorylation by ATM/ATR inhibits SIRT1
deacetylase in response to DNA damage. J Mol Cell Biol. 4:294–303.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu L, Wang P, Liu X, He D, Liang C and Yu
Y: Exogenous NAD(+) supplementation protects H9c2 cardiac myoblasts
against hypoxia/reoxygenation injury via Sirt1-p53 pathway. Fundam
Clin Pharmacol. 28:180–189. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Marfe G, De Martino L, Tafani M,
Irno-Consalvo M, Pasolini MP, Navas L, Papparella S, Gambacurta A
and Paciello O: A multicancer-like syndrome in a dog characterized
by p53 and cell cycle-checkpoint kinase 2 (CHK2) mutations and
sirtuin gene (SIRT1) down-regulation. Res Vet Sci. 93:240–245.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee CW, Wong LL, Tse EY, Liu HF, Leong VY,
Lee JM, Hardie DG, Ng IO and Ching YP: AMPK promotes p53
acetylation via phosphorylation and inactivation of SIRT1 in liver
cancer cells. Cancer Res. 72:4394–4404. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kriegl L, Vieth M, Kirchner T and Menssen
A: Up-regulation of c-MYC and SIRT1 expression correlates with
malignant transformation in the serrated route to colorectal
cancer. Oncotarget. 3:1182–1193. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schweiger MR, Hussong M, Röhr C and
Lehrach H: Genomics and epigenomics of colorectal cancer. Wiley
Interdiscip Rev Syst Biol Med. 5:205–219. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chong ZZ, Shang YC, Wang S and Maiese K:
SIRT1: New avenues of discovery for disorders of oxidative stress.
Expert Opin Ther Targets. 16:167–178. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hubbard BP, Gomes AP, Dai H, Li J, Case
AW, Considine T, Riera TV, Lee JE, E SY, Lamming DW, et al:
Evidence for a common mechanism of SIRT1 regulation by allosteric
activators. Science. 339:1216–1219. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yao X, Zhao G, Yang H, Hong X, Bie L and
Liu G: Overexpression of high-mobility group box 1 correlates with
tumor progression and poor prognosis in human colorectal carcinoma.
J Cancer Res Clin Oncol. 136:677–684. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Firestein R, Blander G, Michan S,
Oberdoerffer P, Ogino S, Campbell J, Bhimavarapu A, Luikenhuis S,
de Cabo R, Fuchs C, et al: The SIRT1 deacetylase suppresses
intestinal tumorigenesis and colon cancer growth. PLoS One.
3:e20202008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yeung F, Hoberg JE, Ramsey CS, Keller MD,
Jones DR, Frye RA and Mayo MW: Modulation of NF-kappaB-dependent
transcription and cell survival by the SIRT1 deacetylase. EMBO J.
23:2369–2380. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Leko V, Park GJ, Lao U, Simon JA and
Bedalov A: Enterocyte-specific inactivation of SIRT1 reduces tumor
load in the APC(+/min) mouse model. PLoS One. 8:e662832013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Howitz KT, Bitterman KJ, Cohen HY, Lamming
DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL,
et al: Small molecule activators of sirtuins extend
Saccharomyces cerevisiae lifespan. Nature. 425:191–196.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Simic P, Zainabadi K, Bell E, Sykes DB,
Saez B, Lotinun S, Baron R, Scadden D, Schipani E and Guarente L:
SIRT1 regulates differentiation of mesenchymal stem cells by
deacetylating β-catenin. EMBO Mol Med. 5:430–440. 2013. View Article : Google Scholar : PubMed/NCBI
|
